Studies indicate that combining trastuzumab with chemotherapy improves the survival rate of patients afflicted by HER2-positive GC (Meric-Bernstam et al., 2019), while pablizumab has been approved by the FDA for treating PD-L1 positive GC (Kim et al., 2018). This evidence concerns the gene CD274 and gastric cancer.